TILLY BURROUGHS: Open Payments
NPI 1669109641 · KENOSHA, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,266 in 145 payments from 19 companies in 2025. Trend: 2023 $1,464 · 2024 $1,506 · 2025 $2,266
Food & beverage: $2,266
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 12 | $322 |
| Neurocrine BioSciences, Inc. | 17 | $283 |
| Otsuka America Pharmaceutical, Inc. | 18 | $280 |
| Supernus Pharmaceuticals, Inc. | 20 | $262 |
| Teva Pharmaceuticals USA, Inc. | 11 | $200 |
| Janssen Pharmaceuticals, Inc | 16 | $171 |
| ABBVIE INC. | 13 | $160 |
| Axsome Therapeutics, Inc. | 15 | $159 |
| Lundbeck LLC | 7 | $140 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
Products named: ARISTADA, INGREZZA, Qelbree, REXULTI, AUSTEDO XR, VRAYLAR, Auvelity, ABILIFY ASIMTUFII.
Industry payments across WI — which companies pay providers there.
